title: Increased expression of microRNA-301a in nonsmall-cell lung cancer and its clinical significance.
abstract: OBJECTIVE
  Recently, accumulating evidence indicates that dysregulation of microRNAs is associated with the initiation and progression of cancer. Oncogenic miR-301a has been reported upregulation and associated with tumorigenesis and progression in various types of cancer. The aim of this study was to investigate the expression of miR-301a in nonsmall-cell lung cancer. (NSCLC), and to assess its association with malignancy, metastasis and prognosis.
  
  
  METHODS
  total of 88 NSCLC patients (females = 21 and males = 67), aged 15-81 years were included in the study. miR-301a expression in tumor tissue was estimated by real-time quantitative reverse transcription polymerase chain reaction.
  
  
  RESULTS
  miR-301a was significantly upregulated in NSCLC tissues compared with their paired adjacent nontumor tissues. (P < 0.001). Increased expression of miR-301a was detected in tumors with lymph node metastases. (P =0.003). In addition, high miR-301a expression was significantly associated with poorly differentiation. (P =0.015), lymph node metastasis. (P =0.013) and advanced tumor-node-metastasis. (TNM) stage. (P =0.018). A. comparison of survival curves of low versus high expressers of miR-301a revealed a highly significant difference in NSCLC, which suggests that overexpression of miR-301a is associated with a poorer disease-free survival (DFS) (P =0.002). Moreover, multivariate Cox proportional hazard regression analyses revealed that the miR-301a overexpression was an unfavorable prognostic factor for disease-free survival in addition to TNM stage.
  
  
  CONCLUSIONS
  miR-301a may represent a novel prognostic indicator, a biomarker for the early detection of lymph node metastasis and a therapeutic target in NSCLC.
authors.affiliation: Department of Emergency Medicine, The Affiliated Hospital of Weifang Medical University, No. 465, Kuiwen, Weifang, Shandong, 261031, People's Republic of China.
authors.forename: You-Kui
authors.initials: YK
authors.lastname: Shi
authors.affiliation: Department of Emergency Medicine, The Affiliated Hospital of Weifang Medical University, No. 465, Kuiwen, Weifang, Shandong, 261031, People's Republic of China.
authors.forename: Quan-Ling
authors.initials: QL
authors.lastname: Zang
authors.affiliation: Department of Oncology, The Affiliated Hospital of Weifang Medical University, No. 465, Kuiwen, Weifang, Shandong, 261031, People's Republic of China.
authors.forename: Gui-Xin
authors.initials: GX
authors.lastname: Li
authors.affiliation: Department of Oncology, The Affiliated Hospital of Weifang Medical University, No. 465, Kuiwen, Weifang, Shandong, 261031, People's Republic of China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Huang
authors.affiliation: Department of Cardiothoracic Surgery, The Affiliated Hospital of Weifang Medical University, No. 465, Kuiwen, Weifang, Shandong, 261031, People's Republic of China.
authors.forename: Shi-Zhong
authors.initials: SZ
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000235:genetics* / Q000401:mortality; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000401:mortality; D008207:Lymphatic Metastasis; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D012307:Risk Factors
chemical_list: D014408:Biomarkers, Tumor; C546086:MIRN30b microRNA, human; D035683:MicroRNAs